Binimetinib (MEK162, ARRY-162, ARRY-438162)

Catalog No.S7007

Binimetinib (MEK162, ARRY-162, ARRY-438162) Chemical Structure

Molecular Weight(MW): 441.23

Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Phase 3.

Size Price Stock Quantity  
USD 97 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 10 Publications

7 Customer Reviews

  • Whole-cell lysates from NRAS- or BRAF-mutant melanoma cells treated with encorafenib or/and binimetinib or DMSO as a control for 24 hours were subjected to Western blot analysis to detect pERK, ERK, and b-actin. The experiment shown is a representative of three independent experiments.

    Clin Cancer Res, 2017, 23(20):6203-6214. Binimetinib (MEK162, ARRY-162, ARRY-438162) purchased from Selleck.

    A875 and WM2664 cells were transfected with Myc-NRAS plasmid (2.5 ug, 24 h) and NRAS siRNA (10 nM, 48 h), respectively, then were treated with indicated inhibitor for 48 h. The activation of indicated molecules and NRAS were examined by Western Blotting (A and D). The relative phosphorylation levels of signalling mediators were quantified by measuring the relative intensity of phosphorylated bands to the corresponding total bands (BeC and EeF; presented as mean±standard deviation [SD] of three scans)

    Eur J Cancer, 2018, 89:90-101. Binimetinib (MEK162, ARRY-162, ARRY-438162) purchased from Selleck.

  • Cells seeded in 96-well plates (2,000-3,000 cells per well) were cultured in triplicate with or without graded concentrations of MEK1/2 plus/minus 100 μg/mL cetuximab, which were not renewed during the entire period of cell exposure. For each pair of columns, the height of the left columns represents the sum of the toxic effect of each agent and, therefore, the expected toxicity if their effects were additive when used in combination. The total height of the right columns represents the observed toxicity when the agents were used in combination. The difference between the heights of the paired columns reflects the magnitude of antagonism or synergism on cell toxicity between MEK1/2 inhibitors and cetuximab in NRAS+/+ (left panels) and NRASQ61K/+ (right panels) cells. Results are shown as mean (columns) ± SD (error bars) from at least three experiments in which triplicate wells were analyzed.

    Oncotarget, 2016, 7(50):82185-82199. Binimetinib (MEK162, ARRY-162, ARRY-438162) purchased from Selleck.

    H460 cells were either treated with perifosine (3 μM), MEK-162 (1 μM), or combine for 8 h; expression of indicated proteins was tested by Western blots using corresponding antibodies.

    Tumor Biol, 2015, 36: 5699-06. Binimetinib (MEK162, ARRY-162, ARRY-438162) purchased from Selleck.

  • H460 cells were treated with indicated concentration of perifosine (1–3 μM), in the presence or absence of MEK-162 (1 μM) for 48 h, cell apoptosis was tested by either Annexin V FACS assay or histone-DNA apoptosis ELISA assay.

    Tumor Biol, 2015, 36: 5699-06. Binimetinib (MEK162, ARRY-162, ARRY-438162) purchased from Selleck.

    B: ERK and p-ERK1/2 levels in response to MEKi treatment. Tra = trametinib, Ref = refametinib, Sel = selumetinib, Bin = binimetinib. Films were intentionally overexposed to detect signal in lanes with low p-ERK1/2 expression. For each cell line all treatment conditions were performed as part of the same experiment. All experimental findings were confirmed in independent experiments performed in triplicate. Note: membranes incubated with p-ERK1/2 antibody were overexposed to capture all remaining signal after MEKi treatment. WB images have been cut to keep the same sample order. All membranes incubated with the same antibody have been exposed for the same period of time.

    Am J Cancer Res, 2016, 6(10):2235-2251. Binimetinib (MEK162, ARRY-162, ARRY-438162) purchased from Selleck.

  • HepG2 cells, “Pnt-2” primary HCC cells or THLE-2 normal liver cells were pretreated with PD-98059 (1 mM) or MEK-162 (“MEK”, 1 mM) for 1 h prior toWAY-600 (“WAY”, 100 nM) treatment, after applied period, cell viability and apoptosis were tested by MTT assay (F and H).

    Biochem Biophys Res Commun, 2016, 474(2):330-7.. Binimetinib (MEK162, ARRY-162, ARRY-438162) purchased from Selleck.

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Phase 3.
Targets
MEK [1]
(Cell-free assay)
12 nM
In vitro

ARRY-438162 (625 nM) inhibits in vitro osteoclast differentiation with IC50 of 39 nM. ARRY-438162 (10 μM) inhibits in vitro osteoclast resorption with IC50 of 625 nM. ARRY-438162 (2 μM) weakly affects osteoblast differentiation. [2] ARRY-438162 is a recently disclosed potent and selective ATP non-competitive MEK1/2 inhibitor, inhibits pERK in cells with an IC50 of11 nM. [3] MEK162 (1 μM) combined with MK-2206 (2 μM) completely reverses the resistance of RSK-expressing MCF7 cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H727 MXXGeY5kfGmxbjDhd5NigQ>? Mmr6TWM2OD1zMUWgcm0> NUToZnd7OzB|NUK1OlU>
Mel IL NXr3R453S3m2b4TvfIlkcXS7IHHzd4F6 M1;PNWlEPTB;Mz63JOKyKDBwMjFOwG0> M3jwflMxPTVzNUG1
Mel IL/R NWXR[ZhRS3m2b4TvfIlkcXS7IHHzd4F6 M3z4[mlEPTB;Mj63JOKyKDBwMzFOwG0> MWWzNFU2OTVzNR?=
Mel Z NGrWOY5EgXSxdH;4bYNqfHliYYPzZZk> M4rVeWlEPTB;Mz64JOKyKDBwMjFOwG0> MnPIN|A2PTF3MUW=
A375 M3HJV2N6fG:2b4jpZ4l1gSCjc4PhfS=> MWrJR|UxRTlwODFCtUAxNjFizszN NIDVeXA{ODV3MUWxOS=>
Mel Me NU[5NFlES3m2b4TvfIlkcXS7IHHzd4F6 MYnJR|UxRTF|LkOgxtEhOC5|IN88US=> NFXJ[3c{ODV3MUWxOS=>
Mel MTP NV7HbG96S3m2b4TvfIlkcXS7IHHzd4F6 MXzJR|UxRTFyLkKgxtEhOC52IN88US=> M2LTflMxPTVzNUG1
U2OS cells MXPGeY5kfGmxbjDhd5NigQ>? MUGxJO69VQ>? M3PTV21GUzF4MjDicI9kc2WmIFXST{Bi[3SrdnH0bY9vKCiyLVXST|EwOiliaX6gR3o1OTVvdILlZZRm\CCXMl;TJINmdGy| MneyNlkyOzd{NEG=
CHP-212 M1PpfmNmdGxidnnhZoltcXS7IHHzd4F6 M3jkRlEzOMLiaB?= MkXLTWM2OD1yLkCwPFMh|ryP M1e1cFI3QTJ3OESx
SK-N-AS NWWzSHJqS2WubDD2bYFjcWyrdImgZZN{[Xl? M4L3Z|EzOMLiaB?= NWe2e5ZUUUN3ME2wMlA3PyEQvF2= MnjGNlY6OjV6NEG=
SK-N-BE(2) MlTCR4VtdCC4aXHibYxqfHliYYPzZZk> Mn3JNVIxyqCq NWTDTlVsUUN3ME2wMlI5KM7:TR?= MnW3NlY6OjV6NEG=
SJ-NB-10 MWfD[YxtKH[rYXLpcIl1gSCjc4PhfS=> NHfTToYyOjEEoHi= MlnyTWM2OD1zLkG2JO69VQ>? M13BN|I3QTJ3OESx
CHP-134 MXvD[YxtKH[rYXLpcIl1gSCjc4PhfS=> MXSxNlDDqGh? NGXRcGJKSzVyPkG1JO69VQ>? MV:yOlkzPTh2MR?=
Kelly MWTD[YxtKH[rYXLpcIl1gSCjc4PhfS=> MYGxNlDDqGh? NGHnWVZKSzVyPkG1JO69VQ>? NVXLfZExOjZ7MkW4OFE>
LAN-5 MXfD[YxtKH[rYXLpcIl1gSCjc4PhfS=> NELvdlQyOjEEoHi= NUfZN2ROUUN3ME6xOUDPxE1? M{XnV|I3QTJ3OESx
NGP NH\UZWZE\WyuII\pZYJqdGm2eTDhd5NigQ>? MUexNlDDqGh? M2XVUmlEPTB-MUWg{txO NVnQVXN6OjZ7MkW4OFE>
SK-N-DZ NFjRRoZE\WyuII\pZYJqdGm2eTDhd5NigQ>? NILzc2syOjEEoHi= MnLQTWM2OD5zNTFOwG0> M2DueVI3QTJ3OESx
A549 NYPlc3BwS2WubDDjfYNt\SCjc4PhfS=> MVywMEAxNjVuIEGg{txO MYO0PIg> M1\FOoF1KHKnbHH0bZZmdHlibH;3JINwdmOnboTyZZRqd25icnHu[4V{KOLLpDCxJO69VSBqZT7nMkwhOC53IHHu[EAyKM7:TTmgbY5lfWOnZDDHNUBienKnc4S= NYDBfplzOjV7M{eyPVk>
H157 NVfFPI02S2WubDDjfYNt\SCjc4PhfS=> M1PHWFAtKDBwNTygNUDPxE1? NYjhfWE1PDiq NHW5V4hifCC{ZXzheIl3\Wy7IHzve{Bkd26lZX70doF1cW:wIILhcodmeyEkibSgNUDPxE1iKHWu[{4tKDBwNTDhcoQhOSEQvF2pJIlv\HWlZXSgS|Eh[XK{ZYP0 M4L6RVI2QTN5Mkm5
H522 MWXD[YxtKGO7Y3zlJIF{e2G7 NGDQelUxNCByLkWsJFEh|ryP Mo\DOFhp M17hRYF1KHKnbHH0bZZmdHlibH;3JINwdmOnboTyZZRqd25icnHu[4V{KOLLpDCxJO69VSBqZT7nMkwhOC53IHHu[EAyKM7:TTmgbY5lfWOnZDDHNUBienKnc4S= MlH1NlU6Ozd{OUm=

... Click to View More Cell Line Experimental Data

In vivo ARRY-438162 (10 mg/kg, po, bid) reduces disease severity in a dose-related manner in rat collagen-induced arthritis (CIA) and rat adjuvant-induced arthritis (AIA) models. ARRY-438162 (po, bid) inhibits increases in ankle diameter by 27% and 50% at 1 mg/kg and 3 mg/kg in the rat collagen-induced arthritis (CIA) model, while ibuprofen has 46% inhibition. ARRY-438162 (10 mg/kg, po, bid) significantly inhibits lesions (inflammation, cartilage damage, pannus formation and bone resorption) by 32% and 60% at 1 mg/kg and 3 mg/kg in the rat collagen-induced arthritis (CIA) model. ARRY-438162 inhibits AIA ankle diameter 11% and 34% at 3 mg/kg and 10 mg/kg in rat adjuvant-induced arthritis (AIA) models. [1] ARRY-438162 demonstrates dose-related inhibition of ankle swelling in rat adjuvant-induced arthritis (AIA) models, significant at 10 mg/kg and 30 mg/kg when compared to vehicle control. ARRY-438162 demonstrates dose-related inhibition of serum IL-6 concentration in rat adjuvant-induced arthritis (AIA) models, with complete inhibition at 10 mg/kg when compared to vehicle control. ARRY-438162 (30 mg/kg) demonstrates dose-related inhibition of relative spleen weights in rat adjuvant-induced arthritis (AIA) models. ARRY-438162 (30 mg/kg) significantly inhibits bone resorption and inflammation with delayed dosing when compared to vehicle in rat adjuvant-induced arthritis (AIA) models. [2] MEK162 (6 mg/kg, BID) combined with BEZ235 results in a significant reduction of tumor growth in immunodeficient mice injected with MCF7 cells. [4]

Protocol

Animal Research:[4]
+ Expand
  • Animal Models: immunodeficient mice injected with MCF7-RSK4 cells.
  • Formulation: 0.5% Tween-80, 1% carboxymethyl cellulose
  • Dosages: 6 mg/kg
  • Administration: oral
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 88 mg/mL warmed (199.44 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% CMC+0.5% Tween-80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 441.23
Formula

C17H15BrF2N4O3

CAS No. 606143-89-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03878719 Not yet recruiting Melanoma Array BioPharma|Pierre Fabre Laboratories March 2019 Phase 1
NCT03839342 Not yet recruiting Solid Tumor University Health Network Toronto March 2019 Phase 2
NCT03878719 Not yet recruiting Melanoma Array BioPharma|Pierre Fabre Laboratories March 2019 Phase 1
NCT03839342 Not yet recruiting Solid Tumor University Health Network Toronto March 2019 Phase 2
NCT03843775 Recruiting Advanced BRAF Mutant Cancers Memorial Sloan Kettering Cancer Center|Array BioPharma February 14 2019 Phase 1|Phase 2
NCT03843775 Recruiting Advanced BRAF Mutant Cancers Memorial Sloan Kettering Cancer Center|Array BioPharma February 14 2019 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Could please clarify the formulation in vivo for S7007 is clear or not?

  • Answer:

    S7007 can be dissolved in 5% DMSO+45% PEG 300+ddH2O at 5 mg/ml clearly for injection.

MEK Signaling Pathway Map

Related MEK Products0

Tags: buy Binimetinib (MEK162, ARRY-162, ARRY-438162) | Binimetinib (MEK162, ARRY-162, ARRY-438162) supplier | purchase Binimetinib (MEK162, ARRY-162, ARRY-438162) | Binimetinib (MEK162, ARRY-162, ARRY-438162) cost | Binimetinib (MEK162, ARRY-162, ARRY-438162) manufacturer | order Binimetinib (MEK162, ARRY-162, ARRY-438162) | Binimetinib (MEK162, ARRY-162, ARRY-438162) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID